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Abstract: TNKase is a genetically engineered variant of the alteplase molecule. Three different 
mutations result in an increase of the plasma half-life, of the resistance to plasminogen-activator 
inhibitor 1 and of the thrombolytic potency against platelet-rich thrombi. Among available 
agents in clinical practice, TNKase is the most ﬁ  brin-speciﬁ  c molecule and can be delivered as 
a single bolus intravenous injection. Several large-scale clinical trials have enrolled more than 
27,000 patients with acute myocardial infarction, making the use of this drug truly evidence-
based. TNKase is equivalent to front-loaded alteplase in terms of mortality and is the only 
bolus thrombolytic drug for which this equivalence has been formally demonstrated. TNKase 
appears more potent than alteplase when symptoms duration lasts more than 4 hours. Also, 
TNKase signiﬁ  cantly reduces the rate of major bleeds and the need for blood transfusions. The 
efﬁ  cacy of TNKase may be further improved by enoxaparin substitution for unfractionated 
heparin, provided that enoxaparin dose adjustment is made for patients more than 75 years old. 
Hitherto, the small available randomized studies and international clinical registries suggest 
that pre-hospital TNKase is as effective as primary angioplasty, thus laying the foundations for 
a new ﬁ  brinolytic, TNKase-based strategy as the backbone of reperfusion in acute myocardial 
infarction.
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Thrombolytic therapy versus primary angioplasty
Acute myocardial infarction presenting with ST-segment elevation (STEMI) is usually 
precipitated by plaque disruption with coronary thrombosis. The quick recanalization 
by either thrombolysis (TBL) or primary angioplasty (P-PCI) is the most important way 
to improve the short- and long-term prognosis. Current American and European guide-
lines “prefer” P-PCI, usually believed to achieve better coronary recanalization rates, 
prevent re-infarction and, ultimately, improve survival.1 However, many conceptual 
and practical items dispute this presumed superiority of P-PCI (Table 1).
The claim that P-PCI leads to a mortality reduction has never been shown in any 
single trial and is only suggested by an overview of 23 small trials, with only 2 trials 
enrolling more than 1000 patients.2 Furthermore, this small advantage is no longer 
signiﬁ  cant when the comparison is made with the accelerated infusion of alteplase.3 
Too many times have we observed the failure of such positive small meta-analyses, 
such as those evaluating the effects of nitrates or magnesium in acute myocardial 
infarction, or the efﬁ  cacy of angiotensin-II blockers to prevent atrial ﬁ  brillation, or 
the efﬁ  cacy of aspirin to prevent eclampsia.
The frequently quoted mortality reduction observed in patients treated with P-PCI 
in registries is largely biased both by the incapacity of statistical methods, such as 
the propensity score, to take into account important, intangible confounders, and by 
the entry in the P-PCI cohort of only those patients actually being treated and not those 
patients intended to treat.4Vascular Health and Risk Management 2009:5 250
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Currently, only 25% of American hospitals provide 
primary angioplasty and the majority of patients must be 
transferred to receive the mechanical intervention.5 As a 
consequence, only approximately 4% of transferred patients 
receive P-PCI within 90 minutes from ﬁ  rst medical contact.6 
Attempts to improve this situation so far have required 
“huge” efforts, with a negligible mortality yield.7 An increase 
in the number of catheterization laboratories has been pro-
posed to cope with these shortcomings. However, such a 
proliferation dilutes the number of patients treated in each 
catheteriztion laboratory, endangering quality,8 not to say the 
costs of increasing population-based coronary angiograms 
in patients without myocardial infarction. Further difﬁ  cul-
ties arise during weekends and at night,5 again jeopardizing 
quality.
Pre-hospital thrombolytic therapy
On the other hand, TBL can be delivered everywhere and 
particularly when used in the pre-hospital setting is extremely 
competitive with P-PCI, as demonstrated by the CAPTIM 
study.9 In the recent, important MINAP registry the pre-
hospital use of TBL (nearly always TNKase) ranked among 
the strongest independent predictors of in-hospital survival 
in the United Kingdom.10
The American College of Cardiology/American Heart 
Association guidelines encourage the recording of the 
12-lead electrocardiogram “on-scene” and performing 
pre-hospital TBL within 30 minutes.1 Indeed, the STEMI 
picture is dominated by time, with the small incremental 
beneﬁ  t of P-PCI rapidly vanishing after 90 minutes after 
ﬁ  rst medical contact, particularly among young patients with 
large myocardial infarction, for whom the equivalence of 
TBL and P-PCI may already be achieved by a delay of only 
45 minutes.11 Since time is so important, it is believed that 
most beneﬁ  t may be achieved by treating as many patients 
as possible in the ﬁ  rst 3 hours from the onset of symptoms, 
regardless of whether TBL or P-PCI is used.12 It is now 
estimated that an efﬁ  cient network can offer pre-hospital 
TBL in the ﬁ  rst 3 hours in approximately 50% to 60% of 
STEMI patients.13
TBL can be further improved by reducing the re-infarction 
rate by adjunctive use of clopidogrel14 and enoxaparin15 as 
soon as possible, ideally pre-hospital.
Pharmacologic properties 
of  TNKase in acute myocardial 
infarction
TNKase consists of the alteplase molecule (with the excep-
tion of three point mutations) and has a molecular weight of 
65,000 kD. Thr103 substitution by Asn and the mutation of the 
sequence Lys296 – His-Arg-Arg to Ala-Ala-Ala-Ala prolong 
the half-life and increase the resistance to plasminogen 
activator inhibitor-1 (PAI-1). Additional substitution of 
Asn117 by Gln results in an 8-fold decrease in clearance and 
in a 200-fold increase in resistance to PAI-1.
Compared with other molecules used in clinical prac-
tice, TNKase has the highest degree of ﬁ  brin speciﬁ  city 
and binding. Fibrin speciﬁ  city, in turn, implies a reduced 
propensity for causing major non-cerebral bleeds, because 
lytic activity is restricted to plasmin on the ﬁ  brin surface, 
thus avoiding the breakdown of ﬁ  brinogen, factor V, factor 
VIII and α2-antiplasmin.16 The TNKase conformational 
change reduces its elimination and prolongs its plasma half-
life (α-half-life 11–20 minutes, β-half-life 41–138 minutes). 
Nitrates do not appear to affect TNKase levels, as opposed to 
what happens with alteplase levels.17 Moreover, the inhibition 
by PAI-1 is reduced 80 times compared with alteplase.
The above properties are interesting in the treatment of 
patients with STEMI, allowing single bolus infusion and pre-
venting drug inactivation at the site of platelet-rich coronary 
thrombosis. In addition, TNKase has more intense anti-
platelet properties both in vitro and in vivo compared with 
those of alteplase.18 In experimental models the thrombolytic 
potency of TNKase is 3-fold higher than that of alteplase.19
Clinical use of   TNKase in acute 
myocardial infarction
The ﬁ  rst experience of dose-testing TNKase in STEMI 
began in the TIMI-10A trial, showing a dose-dependent 
increase in TIMI-3 ﬂ  ow rates in the 5 to 50 mg dose range 
(p = 0.032).20
In the dose-escalating pilot TIMI 10B patency trial, 
involving 886 patients 18 to 80 years old, bolus TNKase 
injection achieved coronary TIMI grade-3 ﬂ  ow rates of 55%, 
63% and 66% at 90 minutes after 30, 40 and 50 mg bolus 
Table 1 Reasons for preferring thrombolysis (TBL) to primary 
angioplasty (P-PCI)
TBL is immediately available everywhere
The time-delay to perform P-PCI exceeds 90 minutes in a large fraction 
of patients
P-PCI does not reduce mortality consistently, particularly vs pre-
hospital TBL
TBL can be improved by new adjunctive treatments (clopidogrel and 
enoxaparin)Vascular Health and Risk Management 2009:5 251
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injection.21 The TIMI-3 ﬂ  ow rate was similar to that observed 
in the control group, receiving front-loaded alteplase.
The safety of TNKase in STEMI was investigated in 
ASSENT-1;22 3235 patients received either 30 or 40 or 
50 mg TNKase as a bolus injection. The total stroke rate at 
30 days was 1.5% and the intracranial hemorrhage (ICH) rate 
was 0.8%, without signiﬁ  cant differences between groups. 
Serious bleeding, requiring blood transfusion, occurred in 
1.4% of patients in the TNKase group and in 7% of those 
treated with front-loaded alteplase. Importantly, TIMI-10B 
and ASSENT-1 showed the importance of reducing the 
heparin dose in conjunction with TNKase, to minimize the 
risk of ICH.23
Survival data with TNKase have been tested in compari-
son with those achieved using front-loaded alteplase in the 
large, multicenter, conﬁ  rmation ASSENT-2 trial. A total 
of 16,949 patients with STEMI in the ﬁ  rst 6 hours from the 
onset of symptoms received either weight-adjusted TNKase 
over 5 to 10 seconds (less than 60 kg: 30 mg; 60–69.9 kg: 
35 mg; 70–79.9 kg: 40 mg; 80–89.9 kg: 45 mg; and more 
than 90 kg: 50 mg) or front-loaded alteplase, along with 
aspirin and reduced-dose unfractionated heparin.24 This was 
an equivalence trial and all-cause mortality at 30 days was 
the primary end-point. There was no difference between 
TNKase and alteplase in mortality (6.18% vs 6.15%) and 
stroke rate, including ICH (0.93% vs 0.94%, respectively). 
Moreover, in the TNKase group there was a decreased rate 
in non-cerebral bleeds (26.43% vs 28.95%, p = 0.0003), 
in major bleeds (4.68% vs 5.94%, p = 0.0002) and in the 
need for blood transfusion (4.25% vs 5.49%, p = 0.0002) 
(Table 2). There was also a tendency for ICH to be 
decreased by TNKase among the high-risk population of 
females of more than 75 years old who weighed 67 kg 
(1.14% vs 3.02%).25 The general ASSENT-2 trial results 
were conﬁ  rmed in all major subgroups, including those 
related to age, gender, infarct location, Killip class and 
diabetes status. Interestingly, mortality was signiﬁ  cantly 
lower in the TNKase group when treatment was given more 
than 4 hours after the onset of symptoms (7.0% vs 9.2%, 
p = 0.018), a ﬁ  nding that could be attributed to the drug’s 
fibrin specificity leading to better dissolution of older 
coronary clots and conﬁ  rms from a clinical standpoint the 
improved pharmacologic proﬁ  le of this molecule.
Among other in-hospital outcomes, TNKase also reduced 
the rate of congestive heart failure (ie, Killip class 1: 6.1% 
vs 7.0%, p = 0.025).
Thus, the ASSENT-2 trial indicates that single-bolus 
TNKase is equivalent to the more complex accelerated 
alteplase infusion, in terms of mortality and mortality/stroke 
combination, with the further advantage of a decrease in 
major bleeding rate. These positive results were persisting 
after 1 year.26
TNKase and the adjunctive use
of antithrombotic therapy
and of mechanical intervention
The possibility of further improving the effects of TNKase 
by means of new adjunctive treatments has been explored in 
ASSENT-3 and ENTIRE-TIMI 23 studies.27,28 In ASSENT-3 a 
total of 6095 patients with STEMI in the ﬁ  rst 6 hours from the 
onset of symptoms were treated with either full-dose TNKase 
plus unfractionated heparin (UFH), full-dose TNKase plus 
enoxaparin (ENOX), or half-dose TNKase plus UFH and 
the GPIIB-IIIA inhibitor abciximab (ABX). Compared 
with UFH, the primary end-point (30-day mortality plus 
Table 2 Clinical studies with TNKase in STEMI
Trial (year) Patients Comparison Main ﬁ  ndings
ASSENT-2 (1999) 16,949 TNKase vs rt-PA TNKase and rt-PA equivalent, ↓ major bleeding with TNKase
ASSENT-3 (2001) 6,095 ENOX vs ABX vs UFHa ENOX and ABX better than UFH
ENTIRE-TIMI 23 (2002) 483 ENOX vs ABX vs UFHa ENOX and ABX better than UFH, ↑ bleeding with ABX
ASSENT-3-PLUS (2003) 1,639 ENOX vs UFHa, pre-hospital delivery ↓ reinfarction with ENOX, ↑ stroke/intracranial bleed
CAPITAL-AMI (2005) 170 F-PCIc vs TNKasea ↓ residual ischemia with F-PCI
ASSENT-4 (2006) 1,667 F-PCIc vs P-PCIb ↑ death/ischemia/bleeding in the F-PCI group
WEST (2006) 304 TNKase vs F-PCIc vs P-PCI TNKase and F-PCI comparable to P-PCI
GRACIA-2 (2007) 212 TNKased vs P-PCI ↑ reperfusion with TNKased Similar ventricular damage
aAll patients in the trial received TNKase.
bP-PCI: Primary angioplasty.
cF-PCI: Primary angioplasty, facilitated by TNKase.
dTNKase followed by routine angioplasty within 3–12 hours (“pharmaco-invasive” approach).Vascular Health and Risk Management 2009:5 252
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in-hospital reinfarction and in-hospital refractory ischemia) 
was reduced by ENOX (11.4% vs 15.4%, p = 0.0002) and 
by the combination of UFH plus ABX (11.1%, p = 0.0001). 
When in-hospital ICH or major bleeds were added to the 
primary end-point (so called efﬁ  cacy plus safety end-point), 
again, a signiﬁ  cant reduction was observed both in the ENOX 
group (13.7% vs 17.0%, p = 0.0037) and in the UFH plus 
ABX group (14.2%, p = 0.01416). ABX increased the rate 
of thrombocytopenia compared to both ENOX and UFH 
(3.2% vs 1.2% and 1.3% respectively, p = 0.0001) and it 
also increased the cost of treatment.29
Similar results were observed in the smaller ENTIRE-
TIMI 23 trial.28 This trial had a design very similar to that 
of ASSENT-3, although there was a further group receiving 
ENOX in combination with ABX and half-dose TNKase. 
Overall, the adjunctive use of ENOX with TNKase, com-
pared with UFH, reduced the combined incidence of death/
myocardial infarction at 30 days (4.4% vs 15.9%, p = 0.005). 
ABX did not further decrease the end-point; rather, ABX 
increased the risk of major bleeding (5.2% vs 2.4% compared 
with UFH alone and 8.5% vs 1.9% compared with ENOX 
alone). Major bleeding was also increased when half-dose 
TNKase was combined with eptiﬁ  batide, a small-molecule 
GP IIB-IIIA inhibitor in the INTEGRITI study.30 In conjunc-
tion with the GUSTO-V data,31 ASSENT-3, ENTIRE-TIMI-
23 and INTEGRITI indicate that GPIIB-IIIA agents should 
not be associated with thrombolytic drugs.
In conclusion, ASSENT-3 and ENTIRE-TIMI 23 showed 
that a much simpler thrombolytic regimen is feasible, permit-
ting bolus administration of both TNKase and of adjunctive 
low-molecular-weight heparin.
This new regimen was tested in the pre-hospital phase of 
STEMI treatment in the ASSENT-3-PLUS study.32 In this 
trial, after electrocardiographic conﬁ  rmation was obtained 
in the ﬁ  eld, 1639 patients were treated with TNKase and 
randomly allocated to ENOX or UFH adjunctive treat-
ment. Of interest, 53% of patients could be treated in the 
ﬁ  rst 2 hours, a much higher proportion compared with that 
observed in previous studies. In the pre-hospital setting 
ENOX tended to reduce the composite of 30-day mortality 
or in-hospital reinfarction or in-hospital refractory ischemia 
(14.2% vs 17.4%, p = 0.08), but there was no difference in 
the efﬁ  cacy plus safety end-point, also including the rate of 
ICH or major bleeding (18.3% vs 20.3%, p = NS). ENOX 
reduced the reinfarction rate (3.5% vs 5.8%, p = 0.028), but 
increased the rate of total stroke (2.9% vs 1.3%, p = 0.026) 
and of ICH (2.20% vs 0.97%, p = 0.047). The increase in 
ICH occurred in the group of patients more than 75 years old. 
A pre-speciﬁ  ed pooled analysis of data from ASSENT-3 
and ASSENT-3-PLUS trials largely conﬁ  rmed the utility of 
using ENOX instead of UFH in conjunction with TNKase, 
reducing the primary efﬁ  cacy end-point (composite of death, 
reinfarction and refractory ischemia) from 16.0% to 12.2%, 
p  0.001 and the primary efﬁ  cacy plus safety (ICH or 
major bleeding) end-point from 18.0% to 15.0%, p = 0.003.33 
Among the 1049 patients who required urgent revasculariza-
tion the ENOX beneﬁ  cial effect was even larger (15.4% vs 
10.1%, p = 0.013). The excess in stroke rates observed with 
ENOX (1.3% vs 0.9%), although not signiﬁ  cant, was mainly 
due to an excess in ICH among women of more than 75 years 
old in ASSENT-3-PLUS.
Following these observations, the intravenous bolus of 
ENOX was omitted and the maintenance dose was reduced 
by 25% in patients of more than 75 years old in the large 
deﬁ  nitive conﬁ  rmation EXTRACT-TIMI 25 trial.15
The role of the routine, immediate use of coronary 
angioplasty (so called “facilitated” angioplasty, F-PCI) after 
treatment with TNKase was ﬁ  rst explored in CAPITAL-
AMI.34 This was a small study randomizing 170 high-risk 
STEMI patients treated with TNKase toward immediate 
revascularization by PCI or to conservative management. 
The primary end-point was the composite of death, rein-
farction, recurrent unstable ischemia, or stroke at 6 months. 
The median time from the onset of symptoms to TNKase 
administration was 120 minutes and the median time from 
symptoms to balloon inﬂ  ation 204 minutes. Overall, the pri-
mary end-point was reduced by immediate PCI from 24.4% 
to 11.6% (p = 0.04), a result driven mainly by the reduction 
in the rate of recurrent unstable ischemia (p = 0.03). There 
were no differences in death, reinfarction, stroke or major 
bleeding.
These encouraging results stimulated the planning of the 
larger ASSENT-4 PCI trial,35 a trial designed to investigate 
whether TNKase facilitation would improve the prognosis 
of patients for whom a time-delay of 1 to 3 hours before 
P-PCI was anticipated. The trial design was open-label and 
the primary end-point was the composite of death or con-
gestive heart failure or shock within 90 days. Only 1667 of 
the originally planned 4000 patients were enrolled, because 
the trial was prematurely interrupted by the data and safety 
monitoring board for an excess of in-hospital mortality in 
the group where P-PCI was facilitated by TNKase (6% vs 
3%, p = 0.0105). The median time from TNKase injection to 
ﬁ  rst balloon inﬂ  ation was 104 minutes. A TIMI-3 ﬂ  ow was 
achieved before P-PCI in 43% of TNKase-treated patients 
and in 15% of patients in the control group (p  0.0001). Vascular Health and Risk Management 2009:5 253
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The primary end-point at 90 days was increased in the 
facilitated group (19% vs 13%, p = 0.0045), along with the 
stroke rate (1.8% vs 0%, p  0.0001). These disappointing 
results have been attributed, in retrospect, to an alleged 
pro-thrombotic effect of TBL and, more convincingly, to 
the risk of creating an intra-plaque hemorrhage by inﬂ  at-
ing the balloon in the ﬁ  rst 2 hours after TBL (ie, in a lytic 
state). In retrospect, the risk of death at 90 days was reduced 
by TNKase facilitation when patients were randomized in 
ambulance (relative risk 0.74, 95% CI  0.24–2.30) and mostly 
increased when patients were recruited in P-PCI capable 
hospitals (relative risk 1.62, 95% CI 0.94–2.81). These 
observation raise important methodological issues about 
ASSENT-4 PCI, since 45% patients were actually enrolled 
in P-PCI capable hospital, a design not exactly germane as to 
deﬁ  ne what is the best strategy for the treatment of patients 
at the earliest point of care, particularly in the pre-hospital 
setting. This holds true particularly when considering that 
the trial was open-label.
More pertinent to investigating the role of TNKase 
facilitation is the WEST study,36 a randomized, open-label, 
feasibility study of 304 STEMI patients enrolled in the com-
munity (40% enrolled pre-hospital). All patients received 
aspirin and ENOX and were randomized to either TNKase, 
or to TNKase followed by PCI within 24 hours (including 
rescue PCI for reperfusion failure) or to P-PCI. The time 
from the onset of symptoms to randomization was 113, 130 
and 176 minutes respectively. There were no differences 
between the three groups in the primary composite of death 
or reinfarction, refractory ischemia, congestive heart failure, 
cardiogenic shock or major ventricular arrhythmia (25% vs 
24% vs 23%, p = NS). In the group receiving plain TNKase 
there was a higher rate of the death/reinfarction combination 
(13.0% vs 6.7% vs 4.0%, p = 0.021), but not of death (4.0% 
vs 1.0% vs 1.0%, p = NS).
Thus, the WEST trial conﬁ  rms the data from CAPTIM:9 
when delivered very rapidly, possibly in the pre-hospital 
phase, TNKase is very competitive with P-PCI and may 
offer a very simple and effective treatment, particularly if 
subsequent PCI is offered to those patients with recurrent 
ischemia or deemed at high clinical risk.
TNKase followed by early routine PCI (within 3–12 hours, 
so called “pharmaco-invasive” approach) has been compared 
with P-PCI in 212 patients enrolled in the GRACIA-2 study.37 
This is a non-inferiority trial designed to evaluate whether 
a lytic strategy represents a reasonable option for STEMI 
patients, irrespective of geographic or logistic barriers, 
when compared with P-PCI. The primary end-points were 
epicardial and myocardial reperfusion and the extent of 
left ventricular damage (as assessed by infarct size and left 
ventricular function). Complete ST-segment resolution at 
the electrocardiogram was observed more frequently in 
the TNKase group (61% vs 43%, p = 0.01), implying an 
improved myocardial perfusion (as measured by the TIMI 
myocardial perfusion grade at 60 minutes).38 Infarct size 
and left ventricular ejection fraction were similar in the two 
groups (Figure 1).
It may be concluded that the results of the WEST study 
are conﬁ  rmed by GRACIA-2, suggesting the comparable 
efﬁ  cacy of TNKase (with rescue/routine PCI) and P-PCI.
Most relevant to pathophysiogy and clinical practice, is the 
ﬁ  nding of GRACIA-2 (in combination with ASSENT-4 PCI) 
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Figure 1 ST-segment complete resolution after PCI and left ventricular ejection fraction in GRACIA-2.
P-PCI = Primary angioplasty.Vascular Health and Risk Management 2009:5 254
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that routine PCI after TNKase should be postponed at least 
3 to 12 hours to achieve the beneﬁ  t.
Conclusions
TNKase treatment of patients with STEMI is truly evidence-
based.
More than 27,000 patients have been enrolled in several 
trials, by different investigators across the world, and address-
ing all major issues: strategy of reperfusion, comparison 
with other thrombolytic agents, choice of the best adjunctive 
anti-thrombotic treatment, and optimal patient management 
after drug injection.
For all the above considerations the American College of 
Chest Physicians (ACCP) recognizes TNKase as a Class 1A 
recommendation in the treatment of STEMI patients within 
12 hours from the onset of symptoms.39
There are indeed several reasons for choosing TNKase 
(Table 3): the easy way it may be used in ambulance (this 
use is also a Class IA ACCP recommendation), the high 
thrombolytic potency with a decreased risk of inducing 
major bleeds, and the really competitive results that may be 
expected for that majority of patients presenting in the ﬁ  rst 
3 hours, compared with P-PCI.
Indeed, TNKase is now embraced in many pre-hospital 
thrombolytic reperfusion protocols, such as the Vienna 
STEMI Registry,40 The Mayo Clinic STEMI Protocol,41 and 
The French FAST-MI registry.42
Therefore, a modern, TNKase-based “ﬁ  brinolytic strategy” 
is now offered to the health care system, which may over-
come the huge logistic problems connected with the utopian, 
universal P-PCI implementation.
Pre-hospital TNKase is a real opportunity to offer timely 
reperfusion to as many patients as possible in an easy way, 
an opportunity that the health care system cannot miss.
Table 4 summarizes how TNKase is used in clinical 
practice.
Table 3 Reasons for using TNKase in STEMI patients
TNKase is the most ﬁ  brin-speciﬁ  c thrombolytic agent available
TNKase may be injected by single intravenous bolus in 5–10 seconds
TNKase is as effective as accelerated rt-PA, but with less major bleeding
Pre-hospital TNKase (with rescue/routine PCI) seems as effective as 
primary angioplasty
Table 4 How to use TNKase in STEMI patients
Bolus intravenous injection of TNKase over 5–10 seconds
TNKase dose according to body weight (BW)
  30 mg if BW 60.0 kg
  35 mg if BW between 60.0 and 69.9 kg
  40 mg if BW between 70.0 and 79.9 kg
  45 mg if BW between 80.0 and 89.9 kg
  50 mg if BW 90.0 kg
Adjunctive anti-platelet therapy
  Aspirin: 160–325 mg, followed by 75–162 mg per day, indeﬁ  nitely
  Clopidogrel: 75 mg per day (for at least 28 days if no stenting, 1 month
  if using a bare metal stent, 1 year if using a drug eluting stent)
  Initial clopidogrel dose: 300 mg if age 75 or if a stent is implanted
Adjunctive unfractionated heparin
  Intravenous bolus: 60 U per kg (maximum 4000 U)
  Intravenous infusion: 12 U per kg per hour (maximum 1000 U per hour)
  Target activated partial thromboplastin time: 1.5–2.0 control
  Treatment duration: minimum 48 hours
Adjunctive enoxaparin (only if serum creatinine 2.5 mg/dL in men, 2.0 in women):
  Less than 75 years old: Intravenous bolus of 30 mg
  Less than 75 years old: Subcutaneous injection of 1 mg/kg every 12 hours
  At least 75 years old: No intravenous bolus
  At least 75 years old: Subcutaneous injection of 0.75 mg/kg every 12 hours
  If the creatinine clearance is 30 mL/min: subcutaneous injection every 24 hours
  Treatment duration: for the duration of index hospitalization, up to 8 days
For patients undergoing PCI after TNKase
  If on unfractionated heparin: additional boluses as needed
  If on enoxaparin: no further anticoagulant if 8 hours from the subcutaneous injection
  If on enoxaparin: additional intravenous bolus of 0.3 mg/kg if 8–12 hours
  after the subcutaneous injectionVascular Health and Risk Management 2009:5 255
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